Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Metaboost Rx vs ShedRx

Two GLP-1 desks, one scoreboard. We put Metaboost Rx and ShedRx head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 316 · Grade C

Metaboost Rx

Visit Metaboost Rx Full brief →
vs
Higher Brief ScoreNo. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →

The verdict

ShedRx takes this head-to-head.

ShedRx scores 87 to 60 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.

That doesn't make Metaboost Rx a bad call — it's best for readers who want flat-rate semaglutide/tirzepatide plus a lower-dose microdose track for side-effect-sensitive patients. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
58
86
Supply Reliability
63
86
Transparency
72
84
Access Breadth
50
85
Clinical Oversight
65
85
Track Record
45
86
Metaboost RxBrief Score 60 · 87ShedRx

Price, coverage & the tracker

Metaboost RxShedRx
Brief Score60/100 (C)87/100 (B+)
SemaglutideFrom $249/mo (compounded)$199/mo
TirzepatideFrom $299/mo (compounded)$299/mo
CoverageCoverage not publishedNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerNewnew to the tracker, no prior readingFallingprice falling

Metaboost Rx: New to the tracker on 1 August 2026. The published line reads From $249/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.